Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Memory test scores in frontotemporal dementia (FTD) often appear deceptively normal in the early stages, which is one of the most important diagnostic challenges in this disease. Unlike Alzheimer’s disease, where memory loss is typically the first cognitive symptom, patients with behavioral variant FTD—the most common form of the disease—show less prominent memory impairment. Instead, executive function deficits, personality changes, and language problems are the characteristic early features. This means that standard memory tests alone can miss FTD entirely, leading to delayed diagnoses and inappropriate treatment approaches.
A 61-year-old man might score reasonably well on traditional memory tests while displaying severe social withdrawal, poor decision-making, and inappropriate behavior at work—all classic FTD signs that would be overlooked if clinicians relied primarily on memory performance. FTD is relatively rare but particularly devastating because it strikes people in their most productive years. The disease affects approximately 2.28 per 100,000 people annually and has a global prevalence of 9.17 per 100,000 people. What makes FTD unique is its age of onset: it typically affects individuals under age 65, making it one of the most common causes of early-onset dementia. This means a significant proportion of FTD patients are still in their 50s or early 60s when symptoms begin, a time when cognitive decline is not expected and often goes unrecognized by both patients and their physicians.
Table of Contents
- How Does Frontotemporal Dementia Affect Memory Test Performance?
- Memory Impairment Compared to Alzheimer’s Disease
- Cognitive Testing Standards for Early FTD Detection
- Which Tests Best Identify Genetic Frontotemporal Dementia?
- Common Pitfalls in Early FTD Diagnosis
- Genetic Differences in Cognitive Decline Patterns
- Implications for Clinical Care and Future Monitoring
- Conclusion
How Does Frontotemporal Dementia Affect Memory Test Performance?
Memory impairment in FTD is notably different from the memory loss seen in Alzheimer’s disease. Patients with behavioral variant FTD demonstrate relatively preserved memory function on standard testing, even in moderate disease stages. What they struggle with—and what shows up clearly on detailed cognitive batteries—are executive function tasks: planning, organizing, problem-solving, and cognitive flexibility. A patient might correctly recall a list of words five minutes after hearing them but be unable to plan a simple multi-step task or adjust their behavior when presented with new information. This dissociation between preserved memory and impaired executive function is actually a diagnostic clue that points toward FTD rather than Alzheimer’s.
The distinction matters clinically because it affects which tests clinicians should use. When a physician relies solely on tests like the Mini-Cog or other memory-focused assessments, FTD can easily slip past undetected. A recent study found that 90% of mild FTD patients were correctly classified versus mild Alzheimer’s disease and healthy controls when using comprehensive cognitive testing batteries that included executive function measures. However, if the evaluation focuses narrowly on memory performance, this diagnostic accuracy drops significantly. This is why neuropsychologists who specialize in dementia assessment often administer tests that probe executive function, attention, and language abilities rather than relying on memory scores alone.
Memory Impairment Compared to Alzheimer’s Disease
The cognitive profile of FTD and Alzheimer’s disease are distinctly different, and understanding this difference is essential for early diagnosis. In Alzheimer’s disease, memory loss is the hallmark symptom—patients struggle to remember recent conversations, appointments, and events. Their executive function remains relatively intact until later disease stages. In FTD, the pattern is essentially reversed: memory is less affected, but executive function and behavioral control deteriorate rapidly. A person with early Alzheimer’s might forget that they already ate breakfast but still have the judgment and organizational skills to manage their work and personal life.
A person with early FTD might remember breakfast perfectly but behave inappropriately at a business meeting and make poor financial decisions despite intact memory. One important limitation of this distinction is that it applies most clearly to behavioral variant FTD. Two other FTD variants—progressive nonfluent aphasia (PNFA) and semantic dementia—present with different cognitive patterns, and memory performance in these variants can vary. Additionally, some atypical presentations of FTD can include more prominent memory involvement than typical behavioral variant FTD. This clinical heterogeneity is one reason why FTD is often misdiagnosed as Alzheimer’s disease, primary progressive aphasia treated as a speech therapy problem, or behavioral variant FTD mistaken for psychiatric illness. Patients have been known to spend years in psychiatric treatment for depression or personality disorder before an astute neurologist recognizes the underlying neurodegenerative cause.
Cognitive Testing Standards for Early FTD Detection
The Montreal Cognitive Assessment (MoCA) has emerged as a superior tool for detecting FTD compared to the older Mini-Mental State Examination (MMSE). Research comparing these tests found that the MoCA achieved an area under the curve (a measure of diagnostic accuracy) of 0.87 versus 0.80 for the MMSE when detecting genetic FTD. More importantly, the MoCA distinguished between presymptomatic genetic FTD carriers—people who inherited FTD mutations but have not yet developed symptoms—and healthy controls, while the MMSE failed to detect these early cognitive changes. This difference reflects the test designs: the MoCA includes specific tasks that probe executive function, attention, and complex language processing, while the MMSE relies heavily on memory and simple orientation questions.
The MMSE’s limitations become apparent when evaluating patients with early FTD. A person might score perfectly on the MMSE’s memory sections, orientation questions, and basic language tasks while having significant deficits on executive function items. Additionally, the MMSE can miss subtle language problems that are early hallmarks of FTD variants. Some patients with early semantic dementia or progressive nonfluent aphasia perform normally on MMSE-based screening despite progressive language decline that significantly impacts their daily function and communication. This is a critical warning: a “normal” or “near-normal” MMSE score does not rule out FTD, particularly if accompanied by behavioral changes, executive dysfunction, or language problems.
Which Tests Best Identify Genetic Frontotemporal Dementia?
For families with genetic FTD—caused by mutations in the GRN, MAPT, or C9orf72 genes—the challenge of early detection is even more acute because presymptomatic carriers must be identified before symptoms begin. The MoCA’s superior performance in this context has made it increasingly recommended in genetic FTD screening protocols. Because presymptomatic carriers may have subtle cognitive changes years before they meet diagnostic criteria for FTD, using sensitive tests that detect these early shifts is essential for research participation, family counseling, and planning. A family history of early-onset dementia combined with subtle MoCA changes might prompt genetic testing, whereas the same patient with a normal MMSE might be wrongly reassured.
Comprehensive neuropsychological batteries go even further than the MoCA, testing specific cognitive domains including attention, executive function, memory, language, and visuospatial abilities. These batteries are the gold standard for research studies like the Genetic Frontotemporal Dementia Initiative (GENFI) cohort, which has tracked cognitive changes in genetic FTD carriers over time. However, these comprehensive batteries take 2-4 hours to administer and require specialized neuropsychologists—resources not available in all clinical settings. The practical tradeoff is that brief screening tools like the MoCA offer reasonable accuracy and can be administered in a standard clinic visit, while comprehensive batteries provide detailed cognitive profiles but require more time and expertise. For busy primary care clinicians, the MoCA represents a reasonable middle ground that substantially improves FTD detection compared to the MMSE.
Common Pitfalls in Early FTD Diagnosis
One of the most common diagnostic mistakes is assuming that normal memory performance rules out dementia. Primary care physicians and even some neurologists may tell patients or families, “Your memory is fine, so you don’t have dementia,” without testing executive function or considering behavioral and language changes. This misconception has led to delayed diagnoses, with some FTD patients spending years misdiagnosed with depression, anxiety, bipolar disorder, or personality disorders before the true cause is identified. A 54-year-old executive with increasing irritability, poor judgment in meetings, and inability to organize projects might be referred to a psychiatrist for depression rather than to a neurologist for cognitive testing. Another critical pitfall involves over-reliance on imaging.
Many clinicians assume that if an MRI or CT brain scan looks normal, there cannot be dementia. FTD in its earliest stages may not show obvious brain atrophy on standard imaging, particularly when seeking subtle changes in executive function in presymptomatic carriers. Imaging becomes more clearly abnormal as disease progresses, with characteristic atrophy of the frontal and anterior temporal lobes, but absence of visible atrophy does not exclude FTD diagnosis. This is why cognitive testing is more sensitive than imaging for early detection—changes in test performance often precede visible brain changes by months or years. Families with genetic FTD who understand this principle are more likely to pursue genetic testing and neuropsychological evaluation even when brain scans appear normal.
Genetic Differences in Cognitive Decline Patterns
The specific genetic cause of FTD influences the pattern of cognitive decline, and these patterns show up distinctly on memory and cognitive testing. C9orf72 carriers—the most common genetic cause of FTD in North America and Northern Europe—show lower performance on attention, executive function, and verbal fluency tests from the early disease stages onward. These deficits persist with relatively minimal decline over time, meaning that the cognitive profile remains fairly stable on serial testing. This pattern is very different from progressive decline, which can be observed in other genetic forms. MAPT carriers, by contrast, show lower memory performance and language decline beginning in moderate disease stages, with executive dysfunction developing rapidly at later stages.
This suggests different underlying neurological mechanisms: C9orf72 mutations appear to preferentially damage frontal and executive systems early, while MAPT mutations show a more mixed cognitive profile. These genetic differences have practical implications for families and clinicians. A MAPT carrier with relatively preserved executive function but declining memory performance might be wrongly suspected of having early Alzheimer’s disease. Similarly, a C9orf72 carrier with severe executive dysfunction but relatively preserved memory might confuse clinicians expecting a more “typical” dementia presentation. Understanding these genetic profiles helps explain why family history is so important: if a patient’s parent developed early-onset dementia with prominent personality and behavior changes, genetic FTD testing is warranted even if the parent’s cognitive testing showed preserved memory.
Implications for Clinical Care and Future Monitoring
As neuroimaging and genetic testing become more accessible, the role of cognitive testing is evolving from diagnostic confirmation to baseline assessment and monitoring of progression. Once FTD is diagnosed genetically, serial neuropsychological testing can track how specific cognitive domains change over time, informing discussions about disease trajectory and planning for care needs. For presymptomatic genetic carriers, baseline testing establishes a reference point to detect when cognitive decline begins, allowing timing of clinical trial enrollment or other interventions if they become available. The field of FTD research is moving toward precision medicine approaches where genetic testing, imaging, and cognitive testing together paint a complete picture of disease stage and trajectory.
Future developments in FTD detection may include biomarker testing—blood tests that measure abnormal tau and other proteins associated with FTD—which could eventually replace or supplement some cognitive testing. However, cognitive testing will remain important because it measures functional impact: how the disease is affecting the patient’s actual thinking and behavior, not just the presence of pathological proteins. A patient might have biomarkers indicating FTD but minimal cognitive changes, or might show significant functional decline with subtle cognitive test findings. This is why comprehensive assessment—combining genetics, imaging, biomarkers, and detailed cognitive testing—represents the modern approach to FTD diagnosis and monitoring.
Conclusion
Memory test scores provide important but incomplete information about frontotemporal dementia. Because FTD characteristically spares memory while damaging executive function, behavior, and language, relying on memory testing alone will miss many cases. The Montreal Cognitive Assessment offers substantially better detection of FTD than older tests like the MMSE because it includes executive function tasks, and genetic FTD carriers can be identified through careful cognitive testing years before they develop full clinical symptoms.
Clinicians and families should recognize that normal memory performance does not rule out FTD—in fact, preserved memory alongside executive dysfunction or behavioral change should raise suspicion for this disease. If you or a family member are experiencing cognitive changes, personality shifts, behavioral concerns, or have a family history of early-onset dementia, detailed neuropsychological evaluation by a cognitive specialist is warranted. This evaluation should include tests of executive function, not just memory, and should be combined with neurological examination and imaging. For families with genetic FTD, understanding your genetic status and participating in research studies provides the best opportunity to track disease progression and potentially benefit from emerging treatments.
